Art. 11 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 31 Mar 2004cited 11×

If an applicant withdraws an application for a marketing authorisation submitted to the Agency before an opinion has been given on the application, the applicant shall communicate its reasons for doing so to the Agency. The Agency shall make this information publicly accessible and shall publish the assessment report, if available, after deletion of all information of a commercially confidential nature.

The 10 that are cited most themselves, of 11.

  • Judgment of the General Court (Second Chamber, Extended Composition) of 5 February 2018. Pari Pharma GmbH v European Medicines Agency.Decision

    Regulation No 726/2004 requires the EMA, in Article 11, Article 13(3), Article 36, Article 38(3) and Article 57(1) and (2) thereof, to publish three documents, namely the EPAR, a summary of the characteristics of the medicinal products …

    5 Feb 2018 · 62015TJ0235

  • Ordonnance du président du Tribunal du 20 juillet 2016. PTC Therapeutics International Ltd contre Agence européenne des médicaments.Decision

    … is not possible to qualify as clearly incorrect the applicant’s argument that those regulations — in particular, Articles 11, 12(3), 13(3), 14(11), 24, 26, 57(1), point (1), 57(2), 76 and 80 of Regulation No 726/2004, Article 4(7) of …

    20 Jul 2016 · 62015TO0718(02)

  • Judgment of the General Court (Second Chamber) of 5 February 2018. PTC Therapeutics International Ltd v European Medicines Agency.Decision

    Regulation No 726/2004 requires the EMA, in Article 11, Article 13(3), Article 36, Article 38(3) and Article 57(1) and (2) thereof, to publish three documents, namely the European Public Assessment Report (‘the EPAR’), a summary of the …

    5 Feb 2018 · 62015TJ0718

  • Order of the Vice-President of the Court of 1 March 2017. European Medicines Agency (EMA) v PTC Therapeutics International Ltd.Decision

    In the first place, all documents submitted in connection with an MA application and, in particular, clinical and non-clinical studies, such as the report at issue, should enjoy a general presumption of confidentiality under Regulation No …

    1 Mar 2017 · 62016CO0513

  • Order of the Court (Eighth Chamber) of 14 May 2012. Sepracor Pharmaceuticals (Ireland) Ltd v European Commission.Decision

    14 May 2012 · 62011CO0477

  • Judgment of the General Court (Second Chamber) of 5 February 2018. MSD Animal Health Innovation GmbH and Intervet international BV v EuropeaDecision

    Regulation No 726/2004 requires the EMA, in Article 11, Article 13(3), Article 36, Article 38(3) and Article 57(1) and (2) thereof, to publish three documents, namely the European Public Assessment Report (‘the EPAR’), a summary of the …

    5 Feb 2018 · 62015TJ0729

  • BSG, Urteil vom 13. Dezember 2016 - B 1 KR 10/16 RDecision

    13 Dec 2016 · KSRE144641517

  • Judgment of the Court (First Chamber) of 21 November 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others.Decision

    Article 4 of the regulation lays down that applications for MA are to be submitted to the European Medicines Agency (EMA). The requirements for the submission and examination of those applications are set out in Articles 5 to 15 of the …

    21 Nov 2018 · 62017CJ0029

  • Opinion of Advocate General Sharpston delivered on 31 January 2013. Novartis Pharma GmbH v Apozyt GmbH.Decision

    Articles 4 to 10 set out the procedure relating to applications for the authorisation of a medicinal product. Applications are to be submitted to the European Medicines Agency established under the Regulation, [See Articles 1 and 4(1).] …

    31 Jan 2013 · 62011CC0535

  • Judgment of the General Court (Second Chamber) of 25 September 2018. Amicus Therapeutics UK Ltd and Amicus Therapeutics, Inc. v European MedDecision

    Articles 11, 13(3), 36, 38(3) and 57(1) and (2) of Regulation No 726/2004 require the EMA to publish three documents, namely the European Public Assessment Report (EPAR), a summary of the characteristics of the medicinal products concerned …

    25 Sep 2018 · 62017TJ0033